ROADMAP TO SCALE-UP SUCCESS: FROM BENCH TO MARKET

Zoel Codolà, Ph.D.

Technology Platforms Scientist R&D Department Medichem S.A. (Spain) zcodola@medichem.es www.medichem.es

ChemSpec Europe 2017, May 31th , Munich, Germany



EUROPEAN COMPANY LEADING IN GENERIC APIs & FDFs

With over 40 years of experience. A solid global client base and unparalleled FDA inspection record. Also, leading chlorhexidine manufacturer since 1985. Stable and profitable family-owned organization with 440 employees.







96.000 m² OF MANUFACTURING SITES...



FDA inspected since 1985 - No "Form 483" records in Celrà and Malta APIs plants FDA inspection in our FDF Malta plant expected in 2017 Full respect for the environment at all our sites (ISO certified)





INNOVATION FOCUSED

With large part of our resources (over 25%) devoted to R&D working in an extensive pipeline. Ready to grow in the FDF area after reorganizing and refocusing the business (historically more API minded). Strategy based in looking into unique products with higher added value.





MANUFACTURING CAPABILITIES & TECHNIQUES





Pharmaceutical companies relies on <u>multipurpose batch reactors</u>

Same reactor for activation, coupling, neutralization, extraction, distillation ...

However there is a growing interest on...

- Synthetize highly functionalized and chiral molecules
- Process intensification and cost reduction
- Achieve safer and greener processes
- Enable new technologies for a faster screening/optimization or even new reactivity







uni^{team} medichem que

...and flow chemistry has numerous advantages towards this end...

- Very efficient heat and mass transfer
- Easier impurities control (degradation/consecutive reactions)
- Scale-up effects minimized
- Faster process optimization
- Inline monitoring allows real time performance control



... opening the scope to...

- Highly energetic reactions (thermal safety issues)
- Reactions difficult to scale-up
- Reactions with hazardous/unstable intermediates

FLOWIDIZING PHARMA Identification of right candidates Organometallic reaction Fast and highly exothermic, cryogenic, unstable intermediates Mixing $R_2 \xrightarrow{B^-} R_1 \xrightarrow{-} R_2 \xrightarrow{R_3 \xrightarrow{H}} R_4$ Extreme reaction HOz



Hazardous reagents involved and risk of explosion NO_2 NO_2^+ NO₂

Mixing

uni^{team} products

medichem aue

Heat transfer

conditions



Diazotization reaction

Precipitation of the N₂⁺ salt and shock-sensitivity

 R_1







Identification of right candidates





 $\underset{\text{medichem}}{\text{uni-}}_{\text{products}}^{\text{team}}$





uni^{team} medichem que

HOME-MADE lab equipment

Home-made set-up + Software - $R_3 R_4 HO_2 R_4$ Engineering Dept + Collaboration local University R_4





Schematic flow set-up

Picture of the lab set-up





Comparison between batch and flow







But how to scale up a home-made flow system?

- •Flow industrial equipment not available in-house
- To maintain heat exchange performance similar to lab scale was critical for successful scale-up
- We contacted CORNING, company with experience in the scale-up of flow processes
- <u>1 week</u> feasibility studies at Medichem site
 - G1 Corning reactor Scale-up factor of 3

Glass reactors: visual monitoring of reaction (color)





Scale-up with Corning Technology (Kilo-lab scale)

Technology transfer for scale-up



1/8" tubing

Corning Technology

Heart-shape profile (better mixing) Jacketed reactors (better heat transfer) Feed precooling





Scale-up with Corning Technology (Kilo-lab scale)

Batch Home-made system Corning G1 Advanced-flow reactor





- Target: production of 3 pilot batches of intermediate
- Industrial equipment

G4 Corning reactor → Scale-up *factor of 30* 3 automated dosing lines Atex Compliant (0-20 bar) Huber 620W (7,5 kW at - 40°C)











- Target: production of 3 pilot batches of intermediate
- Industrial equipment

G4 Corning reactor → Scale-up *factor of 30* 3 automated dosing lines Atex Compliant (0-20 bar) Huber 620W (7,5 kW at - 40°C)

> Similar yield / impurity profile as feasibility trials COGS reduction by 30-40 % vs sourced intermediate Reduction of amount of raw materials and solvents

> > Return on investment: 1 year !





Timeline of the project



Main goal accomplished: In-house intermediate → desired availability and quality

Main challenge faced:

Pressure build-up each 2-3 h

Processing time 16 h with 5 min cleaning every 2 h



 $\underset{\text{medichem}}{\text{uni-}}_{\text{products}}^{\text{team}}$



Diazotization reaction

Precipitation of the N₂⁺ **salt and shock-sensitivity**







Hazardous reagents involved and risk of explosion









HOME-MADE lab equipment

Metal-free double piston pumps PTFE pipes and glass vessels







Picture of the lab set-up





HOME-MADE lab equipment

Metal-free double piston pumps PTFE pipes and glass vessels

















Glass-beads packed bed pipe

uni^{team} medichem que

Scale-up: Renting equipment at kilo-lab scale (x8) for paramters fine tunning was needed to guarantee seamless scale-up to production









- Target: production of 3 pilot batches of intermediate
- Industrial equipment

Medichem SiC industrial reactor → Scale-up factor of 30 from kilo-lab
2 automated dosing lines Atex Compliant (0-20 bar)
Huber 620W

Similar yield / impurity profile as feasibility trials
 COGS reduction by 23 % compared to batch
 Easier work-up due to a change of solvent for the nitration
 Safety increased! Max. volume of reaction mixture < 1 L





Timeline of the project



Main goal accomplished:In-house intermediate \rightarrow desired availability and qualityFlow step to be included in the DMF of two internal APIs

Flow optimization can be very fast! From lab to first validation batch in less than one year





N-

`R₁

N₂⁺Cl

HCI

R₁

 NH_2





Diazotization reaction

Batch reaction

Precipitation of the N₂⁺ *salt and shock-sensitivity*



Strict temperature control during the reaction (N₂⁺ decomposition) 56 % yield Limited batch size (0.5 kg) due to the possibility of shock-friction

sensitivity (precipitation of N_2^+ Cl salt)





Diazotization reaction

Precipitation of the N₂⁺ salt and shock-sensitivity



Schematic flow set-up

Picture of the lab set-up





Comparison between batch and flow







Direct scale-up

Direct scale-up expected!

Feasibility and optimization performed at lab scale with seamless scale-up expected up to production scale.









Timeline of the project



Main goal accomplished: First synthesis of an API (final step) in flow

- Better control of impurities
- Safer scale-up
- Possibility to work under oversaturated conditions during short RT

Scale-up planned for the next summer!





OUR STRATEGY TO DETECT FLOW CANDIDATES

• Flow is now took into consideration for ALL existing/incoming projects when it supposes a competitive advantage.

- ✓ Fast kinetics (i.e. cryogenic)
- ✓ Mass transfer limitation
- Very exothermic/endothermic reactions
- ✓ Hazardous/unstable intermediates
- ✓ Limitation of the solvent temperature
- ✓ Critical uniformity of the residence time (scale-up effect)







FROM BENCH TO MARKET

- We are able to develop, scale-up and validate flow chemistry processes under GMPs.
- Flow technology is considered indistinctly for intermediates and API
- We have a multipurpose industrial flow system installed in a GMP and FDA inspected API manufacturing plant.
- Flow equipment is portable and installable in any of our plants.

THANKS TO... ALL THE MEDICHEM TEAM

medichem

.... AND TO ALL OF YOU FOR YOUR KIND ATTENTION!!

ChemSpec Europe 2017, May 31th , Munich, Germany



ROADMAP TO SCALE-UP SUCCESS: FROM BENCH TO MARKET

Zoel Codolà, Ph.D.

Technology Platforms Scientist R&D Department Medichem S.A. (Spain) zcodola@medichem.es www.medichem.es

ChemSpec Europe 2017, May 31th , Munich, Germany

